Cargando…
Correction to: One‐Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus‐Eluting Stents in High Bleeding Risk Patients
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496304/ https://www.ncbi.nlm.nih.gov/pubmed/35862226 http://dx.doi.org/10.1161/JAHA.121.020787 |
Ejemplares similares
-
One‐Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus‐Eluting Stents in High Bleeding Risk Patients
por: Pivato, Carlo A., et al.
Publicado: (2022) -
Comparison of 6-Month and Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Biodegradable Polymer Everolimus-Eluting Stent
por: Yoon, Yong-Hoon, et al.
Publicado: (2022) -
Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent
por: Dalos, Daniel, et al.
Publicado: (2016) -
One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial
por: Natsuaki, Masahiro, et al.
Publicado: (2015) -
Correction to: Safety of 3‐Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus‐Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART‐CHOICE Trial
Publicado: (2021)